title: [An optimum dose-finding study of HR810 (CPR) in chronic respiratory tract infections].
abstract: In order to determine the optimal dose of cefpirome sulfate (HR810, CPR) against respiratory tract infections (RTI), an optimal dose-finding study was conducted on cases of chronic RTI, and the clinical properties of the drug were compared with those of ceftazidime (CAZ). Inpatients with chronic RTI were randomly assigned to 3 groups: an HR 0.5 g group, receiving 0.5 g X 2/day of CPR an HR 1.0 g group, receiving 1.0 X 2/day of CPR and a CAZ group, receiving 1.0 g X 2/day of CAZ. As a rule, the drugs were administered by intravenous drip infusion for 14 days, after which period clinical efficacy, bacteriological response, safety, and utility were investigated. Of the total 121 cases, 106 were subject to analysis of clinical efficacy, including 38 cases in the HR 0.5 g group, 32 in the HR 1.0 g group, and 36 in the CAZ group. Efficacy rates in the assessment by the committee were 84.2% for the HR 0.5 g group, 75.0% for the HR 1.0 g group, and 86.1% for the CAZ group, without any significant difference between the 3 groups. The bacterial elimination rates were 73.9%, 75.0% m and 88.5%, respectively, without any significant difference between the 3 groups. Associated reactions were noted in 2 of 36 cases in the HR 1.0 g group (eruption and diarrhea), but not in the other 2 groups. The incidence of abnormal clinical laboratory findings was 23.1% in the HR 0.5 g group, 22.2% in the HR 1.0 g group, and 22.5% in the CAZ group, without any significant difference between the 3 groups. Utility rates were 84.2% for the HR 0.5 g group, 74.2% for the HR 1.0 g group, and 86.1% for the CAZ group, without any significant difference between the 3 groups. The HR 0.5 g and 1.0 groups showed no difference in clinical efficacy, bacteriological response, safety, and utility against RTI, and the results of both groups were about equal to those of the CAZ group.
authors.affiliation: Department of Medicine, Kawasaki Medical School and Related Hospitals.
authors.forename: R
authors.initials: R
authors.lastname: Soejima
authors.forename: J
authors.initials: J
authors.lastname: Hino
authors.forename: M
authors.initials: M
authors.lastname: Sumi
authors.forename: N
authors.initials: N
authors.lastname: Okimoto
authors.forename: S
authors.initials: S
authors.lastname: Yagi
authors.forename: K
authors.initials: K
authors.lastname: Tsukiyama
authors.forename: T
authors.initials: T
authors.lastname: Matsushima
authors.forename: M
authors.initials: M
authors.lastname: Kawanishi
authors.forename: Y
authors.initials: Y
authors.lastname: Hiraga
authors.forename: M
authors.initials: M
authors.lastname: Ohmichi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D000097572:Cefpirome
chemical_list: D002442:Ceftazidime; D002511:Cephalosporins; D000097572:Cefpirome